Treatment with IMOD™ as a novel immune modulator in HIV positive patients

Journal of AIDS and Clinical Research

Volumn 3, Issue 9, 2012, Pages

  SeyedAlinaghi, Seyed Ahmad ^a   Paydary, Koosha ^a,b   Emamzadeh Fard, Sahra ^a,b   Mohraz, Minoo ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84879811697     PISSN: None     EISSN: 21556113     Source Type: Journal    
DOI: 10.4172/2155-6113.1000180     Document Type: Letter

References (16)

1. Fellay J, Boubaker K, Ledergerber B, Bernasconi E, Furrer H, et al. (2001) Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 358: 1322-1327.
2. Murphy RA, Sunpath H, Kuritzkes DR, Venter F, Gandhi RT (2007) Antiretroviral Therapy-Associated Toxicities in the Resource-Poor World: the Challenge of a Limited Formulary. J Infect Dis 196: S449-S456.
3. Novitsky YA, Madani H, Gharibdoust F, Farhadi M, Farzamfar B, et al. (2007) EU Patent Application 087825.
4. Hunt PW, Deeks SG (2006) Immune-based therapy for HIV infection: are acute and chronic HIV infection different diseases? J Infect Dis 194:1632-1634.
5. Rizzardi GP, Harari A, Capiluppi B, Tambussi G, Ellefsen K, et al. (2002) Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest 109: 681-688.
6. Kanter M, Coskun O, Budancamanak M (2005) Hepatoprotective effects of Nigella sativa L and Urtica dioica L on lipid peroxidation, antioxidant enzyme systems and liver enzymes in carbon tetrachloride-treated rats. World J Gastroenterol 11: 6684-6688.
7. Schinella GR, Giner RM, Mordujovich BP, Rhos JL (1998) Anti-inflammatory effects of South American Tanacetum vulgare. J Pharm Pharmacol 50: 1069-1074.
8. Ninomiya K, Matsuda H, Kubo M, Morikawa T, Nishida N, et al. (2007) Potent anti-obese principle from Rosa canina: structural requirements and mode of action of trans-tiliroside. Bioorg Med Chem Lett 17: 3059-3064.
9. Chrubasik JE, Roufogalis BD, Wagner H, Chrubasik S (2007) A comprehensive review on the stinging nettle effect and efficacy profiles. Part ll: urticae radix. Phytomedicine 14: 568-579.
10. Mohraz M, Kheirandish P, Kazerooni PA, Davarpanah MA, Shahhosseini MH, et al. (2009) A clinical trial on the efficacy of IMOD in AIDS patients. Daru 17: 277-284.
11. Kheirandish P, Mohraz M, Farzamnfar B, Abdollahi M, Shahhosseini MH, et al. (2009) Preclinical and phase 1 clinical safety of Setarud (IMOD), a novel immunomodulator. Daru 17: 148-156.
12. Mohraz M, Sedaghat A, SeyedAlinaghi SA, Asheri H, Mohammaddoust S, et al. (2012) Post marketing surveillance on safety and efficacy of IMODTM in Iranian patients with HIV/AIDS. Infectious Disorders-Drug Targets: In press.
13. Khorram Khorshid HR, Abdollahi M, Novitsky YA, Shahhosseiny MH, Sadeghi B, et al. (2008) Studies on potential Mutagenic and Genotoxic activity of Setarud. Daru 16: 223-228.
14. Khorshid HR, Azonov JA, Novitsky Y, Farzamfar B (2008) Hepatoprotective effects of setarud against carbon tetrachloride-induced liver injury in rats. Indian J Gastroenterol 27: 110-112.
15. Roca B, Gómez CJ, Arnedo A (1999) Stavudine, lamivudine and indinavir in drug abusing and non-drug abusing HIV-infected patients: adherence, side effects and efficacy. J Infect 39: 141-145.
16. Gifford AL, Collins R, Timberlake D, Schuster MA, Shapiro MF, et al. (2000) Propensity of HIV patients to seek urgent and emergent care. HIV Cost and Services Utilization Study Consortium. J Gen Intern Med 15: 833-840.